Pancreatic Cancer Research

ResearcherNagoya UniversityActive in the last 2 years

Fuminori Sonohara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6438-2122; OpenAlex author ID A5017952316. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2018: 4 papers · 2019: 4 papers · 2020: 8 papers · 2021: 6 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 26

  1. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.17520↗
  2. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003945↗
  3. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  4. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation… Co-author DOI 10.1245/s10434-022-12039-5↗
  5. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00595-020-02220-2↗
  6. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Co-author DOI 10.1097/mpa.0000000000001712↗
  7. Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. Co-author DOI 10.1186/s13148-021-01165-8↗
  8. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08990-w↗
  9. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  10. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. Co-author DOI 10.21873/anticanres.15189↗
  11. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  12. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… Co-author DOI 10.1002/jhbp.748↗
  13. Clinical impact of additional therapy for residual pancreatic cancer. First author DOI 10.1007/s00595-019-01900-y↗
  14. Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001559↗
  15. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07981-w↗
  16. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08047-7↗
  17. Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14138↗
  18. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13010036↗
  19. Effects of duration of initial treatment on postoperative complications in pancreatic cancer. Co-author DOI 10.1002/jhbp.622↗
  20. Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. Co-author DOI 10.1016/j.ejso.2019.05.019↗
  21. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.01.012↗
  22. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  23. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-28253-9↗
  24. Features of Immune Cells and the Tumor-Associated Stroma Tango as Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.10.008↗
  25. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Co-author DOI 10.1097/mpa.0000000000001186↗
  26. Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6699-8↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasuhiro Kodera · 25 shared papers, 2018–2025 · strength 2.61
  2. Masamichi Hayashi · 23 shared papers, 2018–2025 · strength 2.35
  3. Suguru Yamada · 23 shared papers, 2018–2022 · strength 2.26
  4. Mitsuro Kanda · 16 shared papers, 2018–2025 · strength 1.66
  5. Tsutomu Fujii · 17 shared papers, 2018–2022 · strength 1.62
  6. Norifumi Hattori · 6 shared papers, 2018–2025 · strength 0.70
  7. Masaya Suenaga · 6 shared papers, 2018–2021 · strength 0.47
  8. Ajay Goel · 3 shared papers, 2018–2022 · strength 0.44
  9. Mitsuru Tashiro · 4 shared papers, 2018–2020 · strength 0.35
  10. Nobuhiko Nakagawa · 2 shared papers, 2020–2025 · strength 0.32
  11. Nobutake Tanaka · 3 shared papers, 2018–2022 · strength 0.30
  12. Yuki Sunagawa · 3 shared papers, 2020–2021 · strength 0.30
  13. Susan Tsai · 2 shared papers, 2022 · strength 0.27
  14. Song Cheol Kim · 2 shared papers, 2022 · strength 0.27
  15. Daniel D. Von Hoff · 2 shared papers, 2022 · strength 0.27
  16. Daishi Morimoto · 3 shared papers, 2018–2020 · strength 0.25
  17. Masaya Yamanaka · 2 shared papers, 2021–2022 · strength 0.24
  18. Tomohisa Otsu · 1 shared paper, 2025 · strength 0.22
  19. Haruyoshi Tanaka · 1 shared paper, 2025 · strength 0.22
  20. Nao Takano · 2 shared papers, 2019–2021 · strength 0.20
  21. So Yamaki · 2 shared papers, 2020–2021 · strength 0.19
  22. Sohei Satoi · 2 shared papers, 2020–2021 · strength 0.19
  23. Joji Kitayama · 2 shared papers, 2020–2021 · strength 0.19
  24. Tomohisa Yamamoto · 2 shared papers, 2020–2021 · strength 0.19
  25. Mitsugu Sekimoto · 2 shared papers, 2020–2021 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.